PRESS RELEASES

Webcast
Cytokinetics Analyst & Investor Day: Charting the Commercial Course
Oct 7, 2021 8:30 AM EDT

Press Release Archive 1998-2005

Date	Title
September 23, 2021	Cytokinetics to Host Analyst & Investor Day on October 7, 2021	link
September 12, 2021	Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting	link
September 8, 2021	Cytokinetics to Participate in September Investor Conferences	link
September 7, 2021	Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting	link
September 1, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
August 31, 2021	Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF to Be Presented in Late Breaking Clinical Trials Session at the HFSA Annual Scientific Meeting	link
August 19, 2021	Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA	link
August 5, 2021	Cytokinetics Reports Second Quarter 2021 Financial Results	link
August 2, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
August 2, 2021	Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis	link
July 23, 2021	Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	link
July 22, 2021	Cytokinetics to Announce Second Quarter Results on August 5, 2021	link
July 20, 2021	Cytokinetics Announces Pricing of Public Offering of Common Stock	link
July 19, 2021	Cytokinetics Announces Proposed Public Offering of Common Stock	link
July 19, 2021	Cytokinetics Announces Positive Topline Results of REDWOOD-HCM	link
July 1, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
June 30, 2021	Cytokinetics Announces Additional Results From GALACTIC-HF Presented at the European Society of Cardiology Heart Failure 2021	link
June 23, 2021	Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress	link
June 15, 2021	Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction	link
June 2, 2021	Cytokinetics to Participate in Upcoming Investor Conferences	link
June 1, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
May 19, 2021	Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS	link
May 17, 2021	Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology	link
May 16, 2021	Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)	link
May 10, 2021	Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session	link
May 6, 2021	Cytokinetics Reports First Quarter 2021 Financial Results	link
May 6, 2021	Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM	link
May 5, 2021	Cytokinetics to Hold Annual Meeting of Stockholders	link
May 4, 2021	Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment	link
May 3, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
April 22, 2021	Cytokinetics to Announce First Quarter Results on May 6, 2021	link
April 12, 2021	Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting	link
April 5, 2021	Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference	link
April 2, 2021	Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting	link
April 1, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
March 18, 2021	Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)	link
March 2, 2021	Cytokinetics to Participate in Upcoming Investor Conferences	link
February 26, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
February 26, 2021	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day	link
February 25, 2021	Cytokinetics Reports Fourth Quarter 2020 Financial Results	link
February 18, 2021	Cytokinetics Names Muna Bhanji to Board of Directors	link
February 11, 2021	Cytokinetics to Announce Fourth Quarter Results on February 25, 2021	link
February 2, 2021	Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants	link
February 1, 2021	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
January 13, 2021	Cytokinetics Announces First Patient Dosed in Cohort 2 of REDWOOD-HCM	link
January 11, 2021	Cytokinetics Granted Orphan Drug Designation for CK-3773274 for the Treatment of Hypertrophic Cardiomyopathy	link
January 6, 2021	Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference	link

INVESTORS & MEDIA

PRESS RELEASES

Keyword Search